Next 10 |
CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, May 2, 2024, at 8:00 a.m...
– Report Highlights Company’s Focus on Red Blood Cell Health; Diversity, Equity & Inclusion; and Strong Corporate Governance – – Aligns with the Sustainability Accounting Standards Board (SASB) Standards for the Biotechnology and Pharmaceuticals Industry ...
2024-03-10 10:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the Leerink Partners Global Biopharma Conference o...
2024-02-15 14:08:04 ET Agios Pharmaceuticals (AGIO) Q4 2023 Earnings Conference Call February 15, 2024 8:00 AM ET Company Participants Chris Taylor - Vice President, Investor Relations and Corporate Communications Brian Goff - Chief Executive Officer Cecilia Jone...
2024-02-15 07:01:06 ET More on Agios Pharmaceuticals Agios Is A Gem, But It Will Need Patience (Rating Upgrade) Agios Pharmaceuticals: Strong Thalassemia Data Makes A Tempting Bull Case Agios Pharmaceuticals Q4 2023 Earnings Preview AIM stock dips amid mixed ...
– Announced Positive Results from the Phase 3 ENERGIZE Study of Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia – – Presented Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ...
Propanc Biopharma Inc (PPCB) is expected to report for Q2 2024 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 Arch Resources Inc. Class A (ARCH) is expected to report $6.9 for Q4 2023 Bloom Energy Corporation Class A (BE) is expected to report $-0.0...
2024-02-14 14:05:57 ET More on Agios Pharmaceuticals Agios Is A Gem, But It Will Need Patience (Rating Upgrade) Agios Pharmaceuticals: Strong Thalassemia Data Makes A Tempting Bull Case AIM stock dips amid mixed results for post-COVID fatigue therapy CRISPR, ...
2024-02-08 11:37:46 ET More on Agios Pharmaceuticals, AIM ImmunoTech, etc. CVS Health Corporation (CVS) Q4 2023 Earnings Call Transcript CVS Health FY23 Earnings: Downgrades Inevitable, Long Term Outlook In The Balance CVS Health Corporation 2023 Q4 - Results - Earni...
News, Short Squeeze, Breakout and More Instantly...
Agios Pharmaceuticals Inc. Company Name:
AGIO Stock Symbol:
NASDAQ Market:
Agios Pharmaceuticals Inc. Website:
CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, May 2, 2024, at 8:00 a.m...
– Report Highlights Company’s Focus on Red Blood Cell Health; Diversity, Equity & Inclusion; and Strong Corporate Governance – – Aligns with the Sustainability Accounting Standards Board (SASB) Standards for the Biotechnology and Pharmaceuticals Industry ...
2024-03-10 10:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...